28-DAY ALL CAUSE MORTALITY RATE1

VIBATIV offers comparable efficacy to vancomycin in a difficult-to-treat patient population.

Clinical cure rates for S. aureus bactermia

Of the 797 patients in the Modified All-Treated (MAT) population with at least 1 Gram–positive respiratory pathogen at baseline:1

  • 73 patients had concurrent S. aureus bacteremia at baseline
    • 35 were treated with VIBATIV (21 for MRSA)
    • 38 were treated with vancomycin (24 for MRSA)
  • Clinical cure rates in these patients were 54.3% with VIBATIV and 47.4% with vancomycin

 

* VIBATIV is not indicated for the treatment of bacteremia.